Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Simulations Plus Inc (NQ: SLP )

47.14 +0.42 (+0.90%)
Streaming Delayed Price Updated: 10:30 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Simulations Plus Inc

< Previous 1 2 3 4 Next >
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Axie Infinity Crypto Yield Games
We Pay - You Play - You Earn 
Via IssueWire
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
From Simulations Plus, Inc.
Via Business Wire
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Successfully Delivers FDA-Funded Project
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at the Berenberg Discover AI Seminar
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Enters New Collaboration with Leading Animal Health Company
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports First Quarter Fiscal 2022 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Names Sharlene Evans to Board of Directors
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases GastroPlus® Version 9.8.2
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results
From Simulations Plus, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.